An Open, Study to Assess the Safety of RGTA® (OTR4132) in Patients With Acute Ischemic Stroke (AIS) (MATRISS)
An Open, Multi-centre Study to Assess the Safety and Tolerability of RGTA® (OTR4132) in Patients With Acute Ischemic Stroke (AIS)
Sponsor: Euraxi Pharma
A NA clinical study on Stroke, Acute, this trial is completed. The trial is conducted by Euraxi Pharma and has accumulated 8 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting NA
-
Dec 2023 — Jul 2024 [monthly]
Active Not Recruiting NA
-
Sep 2023 — Dec 2023 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Nov 2022 — Sep 2023 [monthly]
Recruiting NA
Status: Unknown Status → Recruiting
▶ Show 3 earlier versions
-
Oct 2021 — Nov 2022 [monthly]
Unknown Status NA
Status: Not Yet Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Not Yet Recruiting NA
-
Oct 2019 — Jan 2021 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Euraxi Pharma
- European Commission
- Organ, Tissue, Regeneration, Repair and Replacement
For direct contact, visit the study record on ClinicalTrials.gov .